Navigation Links
Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Date:11/12/2012

SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its partner AstraZeneca.  Howard Robin, president and chief executive officer, will host the conference call, which will begin at 8:15 a.m. Eastern Standard Time (EST)/5:15 a.m. Pacific Standard Time (PST).

A live audio-only Webcast of this conference call can be accessed through a link that is posted on the home page of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Thursday, December 13, 2012.

To access the conference call live by telephone, please follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international) 

Passcode: 70465377 (Nektar Therapeutics is the host)

A telephonic replay will also be available shortly following the call and can be accessed by dialing (855) 859-2056 (U.S.); or (404) 537-3406 (international) with a passcode of 70465377.  The replay will be available for approximately four weeks following the call.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

This call will replace the company's regular financial results call which was scheduled for Tuesday, November 13, 2012. 

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Thoratec Schedules First Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. , ... tests, has received two prestigious recognitions that acknowledge the promise of its PWS ... Preora has been named a Top 100 Finalist for the 16th annual Chicago ...
(Date:9/21/2017)... ... September 21, 2017 , ... A ... addiction recovery at a time when Virginia faces an opioid epidemic. ... a staggering increase of 38 percent from 2015, underscoring the need for additional ...
(Date:9/21/2017)... TX (PRWEB) , ... September 21, 2017 , ... ... senior housing operators, announces the acquisition of Isle at Kingwood Assisted Living and ... Kingwood is an established retirement community with 55 assisted living apartments, 43 memory ...
(Date:9/21/2017)... ... September 21, 2017 , ... In the inaugural 30-minute ... Emeritus Professor of Education Gregory A. Smith examines student privacy issues with University ... Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . , Join ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ... (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch of ... easy access to essential information that offers a more comprehensive understanding of the ...
Breaking Medicine News(10 mins):